6-氟-5-甲基喹啉 | 107224-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氟-5-甲基喹啉
• 中文别名: 喹啉,6-氟-5-甲基-(9CI)
• 英文名称: 6-fluoro-5-methylquinoline
• CAS: 107224-22-6
• 化学式: C₁₀H₈FN
• mdl: MFCD18448136
• 分子量: 161.179
• InChiKey: HTPFRHXWHGPOTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-氟-5-甲基喹啉 在 platinum on activated charcoal 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 6-Fluoro-5-methyl-1,2,3,4-tetrahydro-quinoline
  参考文献：
  名称：

  Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid

  摘要：

  The tricyclic quinolone antibacterial agent 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine -2-carboxylic acid has an asymmetric center at position 5 of the molecule. The R and S isomers of the compound have been prepared from the corresponding (R)- and (S)-2,5-dimethyl-6-fluoro-1,2,3,4-tetrahydroquinolines, which were separated via their diastereomeric amides of N-tosyl-(S)-proline. The absolute configuration was established by X-ray analysis of one of the diastereomeric amides. The 5-desmethyl analogue was prepared for antibacterial comparison with the isomers and the racemic mixture. It has now been established that the S isomer is much more active than the R isomer. The 5-desmethyl analogue was found to be more active than the R isomer but not as active as the S isomer or the racemic mixture. The importance of stereochemistry at position 5 in this system has been established.

  DOI：

  10.1021/jm00388a016
• 作为产物：
  描述：

  6-氟喹啉 在 正丁基锂 、 三氯化铝 、 溴 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 5.5h， 生成 6-氟-5-甲基喹啉
  参考文献：
  名称：

  Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid

  摘要：

  The tricyclic quinolone antibacterial agent 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine -2-carboxylic acid has an asymmetric center at position 5 of the molecule. The R and S isomers of the compound have been prepared from the corresponding (R)- and (S)-2,5-dimethyl-6-fluoro-1,2,3,4-tetrahydroquinolines, which were separated via their diastereomeric amides of N-tosyl-(S)-proline. The absolute configuration was established by X-ray analysis of one of the diastereomeric amides. The 5-desmethyl analogue was prepared for antibacterial comparison with the isomers and the racemic mixture. It has now been established that the S isomer is much more active than the R isomer. The 5-desmethyl analogue was found to be more active than the R isomer but not as active as the S isomer or the racemic mixture. The importance of stereochemistry at position 5 in this system has been established.

  DOI：

  10.1021/jm00388a016

文献信息

• PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：US20180170909A1

  公开（公告）日：2018-06-21

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.

  揭示了一种通过调节MALT1来治疗受影响的疾病、综合症、症状和疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、R2、R3、R4、R5、R6、R5、G1和G2在此处定义。
• GERSTER J. F.; ROHLFING S. R.; PECORE S. E.; WINANDY R. M.; STERN R. M.; +, J. MED. CHEM., 30,(1987) N 5, 839-843
  作者：GERSTER J. F.、 ROHLFING S. R.、 PECORE S. E.、 WINANDY R. M.、 STERN R. M.、 +

  DOI：——

  日期：——
• Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid
  申请人：RIKER LABORATORIES, INC.

  公开号：EP0245913B1

  公开（公告）日：1992-03-25
• PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
  申请人：LUZZIO Michael Joseph

  公开号：US20160347737A1

  公开（公告）日：2016-12-01

  PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
• US9845309B2
  申请人：——

  公开号：US9845309B2

  公开（公告）日：2017-12-19